Brief: Oncozenge Has Been Approved For Listing On Nasdaq First North Growth Market
Feb 10 (Reuters) - Moberg Pharma AB (publ) MBPH.ST :
* ONCOZENGE HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET
* MOBERG PHARMA AB (PUBL) - ONCOZENGE FIRST DAY OF TRADING IN ONCOZENGE'S SHARES WILL BE ON
FRIDAY, FEBRUARY 12, 2021
Source text for Eikon: ID:nWkrbXDmG8
Further company coverage: MBPH.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Moberg Pharma AB (publ)
See all newsSweden's Moberg Pharma Q2 loss narrows as revenue rises
Brief: Moberg Pharma Q2 EBITDA SEK -4.3 Million
Brief: Moberg Pharma Names Vaidrius Navikas Chief Medical Officer
Brief: Moberg Pharma And Karo Healthcare Expand Collaboration
Moberg Pharma Q1 revenue rises, losses narrow on Nordic market share gains